KHCF Signs Strategic Partnership Agreement with AstraZeneca

KHCF Signs Strategic Partnership Agreement with AstraZeneca

Amman, 1 June 2022 – HRH Princess Ghida Talal, Chairperson of the King Hussein Cancer Foundation (KHCF) and Center (KHCC) signed a strategic partnership agreement with the pharmaceutical company AstraZeneca, which was represented by Dr. Pelin Incesu, the vice president of its regional office for the Middle East and Africa. In line with the agreement, AstraZeneca will support KHCF’s endeavors toward fighting cancer in Jordan in multiple areas for the next 3 years.

On the occasion of the signing, Princess Ghida said: “We deeply value the strategic partnership between KHCF and AstraZeneca and their support for our efforts in cancer awareness and early detection for breast and lung cancer. We are also delighted to have them as a sponsor of the King Hussein Award for Cancer Research, which plays a vital role in the development of cancer research in our region.”

Dr. Pelin Incesu stated: “AstraZeneca is committed to providing state-of-the-art cancer care to the people of Jordan and the Middle East region. Through our partnership with the King Hussein Cancer Foundation and Center, we hope to educate, train and raise public awareness on the early detection and prevention of cancer, as well as to provide access to life-saving cancer research and treatment. We are also pleased to support the King Hussein research award, which recognizes the contributions of Arab scientists to cancer research.”